Search

Today Sygnature announced that RespiVert Limited has selected Sygnature Chemical Services Ltd to support two new discovery collaborations.  Under the agreement Sygnature will provide medicinal chemistry resources to the programs aimed at identifying novel approaches to respiratory diseases. 
 
Garth Rapeport, CEO of RespiVert commented “Sygnature has been chosen as our major provider of chemistry on the basis of their excellent track record and capability in synthetic and medicinal chemistry"
 
“Sygnature will provide substantial resources to this program in terms of medicinal chemistry, parallel synthesis and purification” said Dr Simon Hirst, CEO of Sygnature.  “RespiVert is an innovative new company and we are very pleased to be working with them at such a crucial stage of their development.  We are confident that our close working style and high transparency will result in a successful relationship.”